Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CORDIS GUIDES ANALYSTS TO NEW RATINGS, STOCK INFLATES 15.8% TO 45

This article was originally published in The Gray Sheet

Executive Summary

CORDIS GUIDES ANALYSTS TO NEW RATINGS, STOCK INFLATES 15.8% TO 45 in July, as several analysts upgrade their ratings of the firm following a July 11 telephone conference in which Cordis President Bob Strauss reassured analysts about the recent downturn in the price of the company's stock. Cordis stock realized the bulk of its gain on the day of the conference, rising 3-3/4 to 40-1/4. The issue gained a total of 6-5/8 points for the month, making it the point leader on "The Gray Sheet" Index of NASDAQ-traded stocks for July.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel